Full-Time

Oncologist

Medical Director, Clinical Development, Mrd

LabCorp

LabCorp

10,001+ employees

Global life sciences R&D services

Compensation Overview

$250k - $360k/yr

+ Annual bonus + Discretionary short-term incentives + Discretionary long-term incentives

Remote in USA + 1 more

More locations: Durham, NC, USA

Hybrid

Remote work is available within the United States; the role requires travel of up to 30%.

MD

Category
Biology & Biotech
Required Skills
Biostatistics
Data Analysis

Get referred to LabCorp

See people who can refer or advise you

Requirements
  • An M.D. or D.O. degree from an accredited medical school is required.
  • Board certification in Medical Oncology is required.
  • At least 5 years of post-fellowship clinical experience treating patients with solid tumors is required.
  • At least 3 years of oncology clinical development, clinical research, clinical trial leadership, or evidence-generation experience in a pharmaceutical, biotechnology, diagnostics, contract research organization, or academic research environment is required.
  • At least 8 years of experience designing, leading, or supporting prospective and/or retrospective clinical studies, including protocol development, endpoint selection, study conduct, data analysis, interpretation, and publication of results is required.
  • At least 5 years of experience working cross-functionally with operations, biostatistics, regulatory affairs, medical affairs, research and development, commercial, and/or market access teams is required.
  • At least 20 presentations delivered to scientific congresses, investigators, key opinion leaders, healthcare providers, advisory boards, or medical education forums are required.
  • Strong understanding of oncology clinical trial methodology, study design, evidence generation, biostatistics, and regulatory requirements is required.
  • Broad knowledge of solid-tumor treatment paradigms, clinical guidelines, biomarkers, and precision-oncology approaches is required.
  • Ability to travel up to 30% is required.
  • Expertise in clinical-trial design, protocol development, biostatistics, epidemiology, and evidence-generation methodologies is required.
  • Strong understanding of regulatory, compliance, and quality frameworks supporting clinical development and diagnostics is required.
  • Ability to evaluate complex scientific and clinical data and translate insights into development strategy is required.
  • Strong strategic-thinking and portfolio-management capabilities are required.
  • Ability to communicate effectively across scientific, clinical, executive, commercial, and payer audiences is required.
  • Ability to lead within highly matrixed organizations and influence without direct authority is required.
  • Strong project-leadership and organizational skills, including the ability to manage multiple high-priority initiatives simultaneously, are required.
  • Ability to navigate ambiguity, solve complex problems, and drive alignment across functions is required.
  • Established relationships with oncology investigators, cooperative groups, academic cancer centers, and professional societies are required.
Responsibilities
  • Serve as the clinical development lead for Labcorp Oncology's minimal residual disease portfolio across solid tumors, providing strategic medical leadership for evidence generation, product development, and clinical adoption initiatives.
  • Develop and execute the clinical development strategy for minimal residual disease and circulating tumor DNA technologies across multiple tumor types and disease settings.
  • Lead the design, development, and execution of clinical studies and evidence-generation programs establishing clinical validity, clinical utility, and health-economic value of minimal residual disease testing.
  • Direct clinical strategies for minimal residual disease applications, including disease detection, recurrence monitoring, treatment-response assessment, risk stratification, treatment selection, and clinical-trial enrichment.
  • Lead studies supporting integration of minimal residual disease testing into clinical-care pathways and routine oncology practice.
  • Partner with operations, biostatistics, research and development, and market access teams on study design, protocol development, endpoint selection, statistical analysis plans, study oversight, and interpretation of results.
  • Recruit, engage, and maintain relationships with principal investigators, cooperative groups, and academic research centers for company-sponsored studies and strategic research collaborations.
  • Oversee study execution, including protocol development, site selection, enrollment strategy, timeline management, budget oversight, and study governance.
  • Translate emerging clinical data into clinical-development recommendations and portfolio strategies.
  • Support investigator-initiated studies, strategic research collaborations, and real-world-evidence programs.
  • Provide medical leadership for the minimal residual disease portfolio throughout the product lifecycle, from concept development through commercialization and lifecycle management.
  • Advise on product-development strategy by identifying unmet clinical needs, new indication opportunities, emerging market trends, and future applications of minimal residual disease technologies.
  • Define intended-use populations, clinical claims, test-report content, validation requirements, and evidence-generation strategies.
  • Partner with research and development teams to guide assay development, biomarker strategy, and next-generation product innovation.
  • Evaluate competitive technologies, emerging biomarkers, and evolving standards of care to inform portfolio strategy and prioritization.
  • Provide clinical input into product roadmaps, indication-expansion opportunities, and future growth areas within the oncology portfolio.
  • Support clinical and scientific evidence development for product launches and lifecycle-management activities.
  • Partner with market access teams on evidence-generation strategies supporting payer coverage, reimbursement, and health-system adoption.
  • Provide medical leadership for studies demonstrating clinical utility, effects on physician decision-making, patient outcomes, and economic value.
  • Support interactions with payers, policy stakeholders, and guideline organizations regarding the clinical rationale and value proposition of minimal residual disease testing.
  • Contribute to inclusion of minimal residual disease testing in clinical-practice guidelines, treatment pathways, and value-based-care models.
  • Build and maintain relationships with oncology investigators, academic medical centers, cooperative groups, and professional societies across solid tumors.
  • Serve as a scientific leader and ambassador for Labcorp Oncology within the oncology community.
  • Represent Labcorp Oncology at scientific congresses, advisory boards, investigator meetings, and industry forums.
  • Engage key opinion leaders in clinical-development strategy, evidence generation, and portfolio planning.
  • Provide medical leadership and post-launch support for minimal residual disease products, including interpretation of clinical evidence and management of complex clinical questions.
  • Serve as a clinical resource for healthcare providers regarding minimal residual disease testing and integration of results into patient management.
  • Oversee medical education initiatives and scientific communications supporting minimal residual disease adoption across solid tumors.
  • Partner with medical affairs, commercial, and marketing teams to develop scientifically accurate educational content.
  • Lead publication planning and support manuscripts, abstracts, presentations, congress submissions, and peer-reviewed publications.
  • Lead, mentor, and develop a team of medical directors and disease-specific clinical leaders.
  • Provide strategic oversight across disease-specific clinical-development programs and evidence-generation plans.
  • Establish portfolio priorities, allocate resources, and align development objectives with organizational goals and business strategy.
  • Develop talent and organizational capabilities supporting Labcorp Oncology's minimal residual disease and precision-oncology programs.
  • Collaborate with medical affairs, operations, biostatistics, regulatory affairs, market access, legal, compliance, commercial, and research and development teams.
  • Support regulatory submissions and interactions by providing clinical expertise and scientific rationale.
  • Partner with commercial leadership to ensure clinical evidence supports product launches and growth initiatives.
  • Monitor emerging scientific, clinical, and competitive developments in oncology, molecular diagnostics, and liquid-biopsy technologies to inform strategy and decision-making.
Desired Qualifications
  • At least 5 years of experience in molecular diagnostics, liquid biopsy, minimal residual disease, circulating tumor DNA, precision oncology, or biomarker-driven clinical development is preferred.
  • At least 5 years of industry experience in diagnostics, biotechnology, pharmaceutical, or life-sciences organizations, with responsibility for oncology product development, medical affairs, clinical development, or translational research is preferred.
  • At least 3 years of experience serving as a medical lead, clinical-development lead, or equivalent leadership role for an oncology assay, biomarker, diagnostic, or therapeutic-development program is preferred.
  • At least 5 years of experience leading oncology clinical-development programs, evidence-generation initiatives, or translational-research activities across multiple solid-tumor indications is preferred.
  • At least 3 studies or evidence-generation programs supporting clinical utility, reimbursement, payer coverage, guideline inclusion, or adoption of oncology diagnostics or precision-medicine products is preferred.
  • At least 3 years of experience partnering with market access teams on evidence-generation strategies supporting value demonstration, reimbursement, and commercial adoption is preferred.
  • At least 3 years of direct people-leadership experience, including management, mentoring, and performance development of physicians, scientists, and/or cross-functional clinical teams is preferred.
  • At least 20 peer-reviewed publications, scientific presentations, and participations at major oncology congresses are preferred.
  • Participation in at least 2 regulatory submissions, product launches, or major lifecycle-management initiatives in oncology, molecular diagnostics, precision medicine, or related therapeutic areas is preferred.

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Get referred to LabCorp

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 5.8% to $3.73 billion; EPS jumped 28.5%.
  • Labcorp raised 2026 guidance on July 30 and authorized another $1.0 billion buyback.
  • August 2026 launches added ColoSense nationwide, Marker, and hepatitis D testing.

What critics are saying

  • Sept. 4, 2026 settlement restricts labcorp.com tracking for two years, hitting digital acquisition.
  • The $35 million AMCA breach settlement keeps privacy liabilities alive through 2026 hearings.
  • Repeated website surveillance scandals invite state AG scrutiny and cripple consumer diagnostics growth.

What makes LabCorp unique

  • Sept. 8, 2026 MLM acquisition gives Labcorp four-continent wholly owned central-lab coverage.
  • Labcorp supported over 85% of FDA-approved 2025 new drugs and therapeutics.
  • Global Trial Connect unifies samples, biomarker data, and investigator workflows across studies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Tuition Reimbursement

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Sep 8th, 2026
Labcorp acquires MLM Medical Labs to become only central laboratory provider with wholly owned network across four continents

Labcorp has acquired MLM Medical Labs, a global central and specialty laboratory provider with operations in the United States, Germany and South Africa. Financial terms were not disclosed. The acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents: North America, Europe, Asia and Africa. MLM operates Africa's first fully CAP-accredited central laboratory. The deal expands Labcorp's presence in key clinical research regions and strengthens its biomarker and specialty testing capabilities. It enhances the company's ability to support multinational clinical trials with consistent scientific, operational and regulatory oversight. Labcorp employs nearly 71,000 people serving clients in approximately 100 countries.

PR Newswire
Sep 5th, 2026
If you conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026, a class action settlement may affect you.

If you conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026, a class action settlement may affect you. Sep 04, 2026, 20:00 ET GREENSBORO, N.C., Sept. 4, 2026 /PRNewswire/ - WHAT IS THIS ABOUT? Plaintiffs allege that Labcorp violated California and Pennsylvania wiretapping laws by facilitating, through third-party tracking technologies, the interception of personally identifiable information and searches that users conducted on Labcorp's website. Labcorp denies these and all other allegations of wrongdoing and liability, and denies all claims asserted against it. Plaintiffs and Labcorp have agreed to a settlement to resolve this lawsuit. The Court has not decided who is right or wrong. WHO IS INCLUDED? The Settlement Classes are defined as follows: * California Settlement Class: All persons in California who conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026. * Pennsylvania Settlement Class: All persons in Pennsylvania who conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026. "Search Queries" means search terms and/or search queries, including but not limited to, entry of any search term(s) into a search bar or search menu on the Labcorp website, www.labcorp.com and its subpages, as well as making any selection(s) from any drop-down menu on the website. WHAT DOES THE SETTLEMENT PROVIDE? If the settlement is approved, or after any potential appeals of that approval are resolved, Labcorp has agreed to the following terms: * Not using or enabling certain tracking technologies (as defined by the settlement agreement, but examples include the Meta Pixel and Google Analytics) on its website, labcorp.com or any of its subpages, for two years; * Conducting an annual review and preparing a compliance report demonstrating that it is not using technologies prohibited by the settlement; * Creating or maintaining a written policy regarding the appropriate use of externally developed tracking technologies on its website; and * Designating a senior employee responsible for overseeing compliance with the above terms. YOUR OPTIONS. The settlement provides only injunctive relief (e.g., business practice terms). Under the settlement terms, Settlement Class Members (except for Settlement Class Representatives) will not release any claims for damages or other monetary relief. If the settlement is approved, you will give up the right to sue Labcorp and other affiliated entities for injunctive relief claims arising from or related to the allegations in this lawsuit. Because the plaintiffs are seeking only injunctive relief and because Labcorp is only agreeing to injunctive relief, Settlement Class Members cannot opt out of the settlement. This means that all members of the Settlement Class will be bound by the settlement, if the Court approves it. If you are a Settlement Class Member, you may object to or comment upon the proposed settlement, explaining why you believe the settlement should not be approved. All objections must be postmarked by November 23, 2026. For more information on how to object, visit www.LaboratoryCorporationWebsiteSettlement.com or call 1-877-378-7520. At the Final Approval Hearing, the Court will consider whether the settlement is fair, reasonable, and adequate, and whether to award attorneys' fees, expenses, and service awards, and in what amounts. If there are objections, the Court will consider them. After the hearing, the Court will decide whether to approve the Settlement. It is not necessary for you to attend this hearing, but you may attend at your own expense. If you have any questions or want more information about the settlement, please visit www.LaboratoryCorporationWebsiteSettlement.com or contact the Settlement Administrator at 1-877-378-7520. SOURCE U.S. District Court for the Middle District of North Carolina

Newsbytes
Sep 1st, 2026
Ultrahuman raises $60M for smart health wearables, valuation jumps 65% to $363M

Ultrahuman, maker of smart health devices including the M1 Live glucose monitoring wearable and Ring Air smart ring, has raised approximately $60 million in its latest funding round. Investors include Qualcomm Ventures, Alpha Wave, LabCorp, Deepinder Goyal, and Blume Ventures. The funding values the startup at $363 million, representing a 65% increase from its previous valuation. Co-founders Mohit Kumar and Vatsal Singhal plan to use the capital for growth, expansion, and general corporate purposes. The round follows Ultrahuman's previous $35 million raise.

Newswire
Aug 31st, 2026
Human Risk Management Leaders from Reveal Risk, Bayer, and Labcorp to speak at HRMCon 2026.

Human Risk Management Leaders from Reveal Risk, Bayer, and Labcorp to speak at HRMCon 2026. Enterprise CISOs and cybersecurity leaders will share real-world lessons for strengthening Workforce Security, advancing Security Behavior Management, and reducing risk across humans and AI agents AUSTIN, Texas, August 31, 2026 (Newswire.com) - Living Security, the global leader in Human Risk Management (HRM), today announced the full speaker roster for HRMCon 2026, its annual Human Risk Management conference taking place September 10 in Austin, Texas, with a live virtual broadcast available worldwide. The lineup brings together enterprise practitioners, analysts, cybersecurity strategists, and workforce security leaders from Forrester, Bayer, Labcorp, Reveal Risk, Cybersecurity Insights, and Living Security. Through real-world case studies and strategic discussions, speakers will examine how organizations are building, funding, and operationalizing Human Risk Management programs to reduce cyber risk across employees, privileged users, contractors, and AI agents. "Security leaders need more than theories about Human Risk Management-they need to understand what it takes to build these programs in the real world," said Ashley Rose, CEO and Co-Founder of Living Security. "This year's speakers will share the decisions, obstacles, data challenges, and business cases behind their programs, giving attendees actionable ideas they can apply within their own organizations." Enterprise Human Risk Management Leaders Share What Works Featured speakers include: * Jinan Budge, Vice President and Research Director at Forrester, providing an independent market outlook on Human Risk Management, changing buyer priorities, and the impact of AI-enabled attacks. * Damon DePaolo of CVS Health, sharing insights from building Human Risk Management programs, including how to align stakeholders, validate assumptions with a live-data proof of concept, and establish success criteria that earn organizational support. * Jennifer Miller of Bayer, explaining how Bayer expanded workforce risk visibility across more than half of its workforce in six months without waiting for a perfect data environment. * Ashley Atiles and Alfonso Mancuso of Labcorp, discussing how behavioral intelligence strengthened phishing-resistant multifactor authentication by revealing user friction, workarounds, resistance, and trust gaps. * Aaron Pritz and Jim Wailes of Reveal Risk, showing how security teams can reduce risk by redesigning high-risk business workflows and making secure behavior easier. * Matthew Rosenquist of Cybersecurity Insights, examining the future of autonomous prevention, adaptive controls, and human accountability as AI agents become part of the workforce. * Gary S. Chan, Security Mentalist and CISO, delivering an interactive closing keynote on the psychology of deception, influence, trust, and security decision-making. The conference will also feature Living Security CEO Ashley Rose and Living Security leaders Kelly Harward and Mike Siegel, who will examine how Human Risk Management must evolve as workforce identities, access patterns, and attack pathways expand beyond employees and email. Workforce Security Lessons from Complex Enterprises Speakers will address some of the most persistent challenges facing enterprise cybersecurity and Workforce Security leaders, including: * Building an enterprise business case for Human Risk Management * Aligning security, identity, compliance, and business stakeholders * Advancing from security awareness training to Security Behavior Management * Applying behavioral intelligence to identity and access controls * Connecting workforce risk signals to real-time security actions * Launching an HRM program with a few critical data sources and expanding over time * Measuring reductions in cyber incidents rather than activities alone * Governing access and accountability across humans and AI agents The sessions will give CISOs, security practitioners, identity leaders, GRC professionals, and Human Risk Management teams actionable guidance for implementing and scaling HRM in complex enterprise environments. Human Risk Management for Humans and AI Agents As AI agents and autonomous systems gain access to enterprise data, applications, and workflows, Workforce Security is expanding beyond employee behavior. Security teams must increasingly assess risk across human and non-human identities while establishing clear governance, access controls, accountability, and measurable security outcomes. HRMCon 2026 will examine how organizations can combine behavioral, identity, and threat intelligence to identify elevated workforce risk, prioritize interventions, and strengthen security controls before incidents occur. HRMCon 2026 will be held September 10, 2026, at The University of Texas Club in Austin, Texas, with a live virtual broadcast available to attendees worldwide. View the full HRMCon 2026 agenda and register to attend in person or virtually at: HRMCon 2026 Human Risk Management Conference About Living Security Living Security is the global leader in Human Risk Management (HRM), helping organizations identify, measure, and reduce workforce cyber risk across humans and AI agents. Its AI-native Human Risk Management platform combines behavioral, identity, and threat intelligence to predict risk, guide response, and prevent cyber incidents before they occur. By connecting security data to measurable business outcomes, Living Security enables organizations to continuously reduce workforce risk while strengthening organizational resilience. Media Contact

Market Chameleon
Aug 31st, 2026
Labcorp launches next generation of Labcorp Global Trial Connect to help sponsors and investigator sites navigate clinical trial complexity.

Labcorp launches next generation of Labcorp Global Trial Connect to help sponsors and investigator sites navigate clinical trial complexity. PRNewswire 31-Aug-2026 7:00 AM Enhanced digital experience designed to improve visibility, simplify workflows and support faster decision-making BURLINGTON, N.C., Aug. 31, 2026 /PRNewswire/ - Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect(TM), the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor(TM) and Labcorp Investigator(TM) portal experiences of Global Trial Connect, providing greater visibility across studies, simplifying workflows and helping sponsors and investigator sites make faster, more informed decisions. "As clinical trials become increasingly complex, sponsors and investigator sites need technology that helps them work more effectively," said Brian Caveney, M.D., EVP and president, Biopharma Laboratory Services and chief medical and scientific officer, Labcorp. "The latest enhancements to Global Trial Connect make it easier to access insights, manage study activities and navigate trial complexity with confidence, allowing customers to focus less on operational tasks and more on advancing research and supporting patients."